Eukaryotic gene regulation implies that transcription factors gain access to genomic information via poorly understood processes involving activation and targeting of kinases, histone-modifying enzymes, and chromatin remodelers to chromatin. Here we report that progestin gene regulation in breast cancer cells requires a rapid and transient increase in poly-(ADP)-ribose (PAR), accompanied by a dramatic decrease of cellular NAD that could have broad implications in cell physiology. This rapid increase in nuclear PARylation is mediated by activation of PAR polymerase PARP-1 as a result of phosphorylation by cyclin-dependent kinase CDK2. Hormone-dependent phosphorylation of PARP-1 by CDK2, within the catalytic domain, enhances its enzymatic capabilities. Activated PARP-1 contributes to the displacement of histone H1 and is essential for regulation of the majority of hormoneresponsive genes and for the effect of progestins on cell cycle progression. Both global chromatin immunoprecipitation (ChIP) coupled with deep sequencing (ChIP-seq) and gene expression analysis show a strong overlap between PARP-1 and CDK2. Thus, progestin gene regulation involves a novel signaling pathway that connects CDK2-dependent activation of PARP-1 with histone H1 displacement. Given the multiplicity of PARP targets, this new pathway could be used for the pharmacological management of breast cancer.
Eukaryotic gene regulation requires that transcription factors gain access to genomic information via processes involving activation and targeting of kinases, histonemodifying enzymes, and chromatin remodelers to chromatin. Post-translational modification of chromatin and chromatin-modifying enzymes is a key component of gene regulation mechanisms; however, in this context, one such modification, poly-(ADP)-ribosylation (PARylation) catalyzed by the PAR polymerase (PARP) family of enzymes, remains poorly characterized (Chambon et al. 1963; Ame et al. 2004) . PARP-1 and PAR play a role in regulating chromatin structure in various physiological contexts and after DNA damage, as PARylation of histones destabilizes nucleosomes (Poirier et al. 1982; Kraus and Lis 2003) . Although PARP-1 was identified as the transcription factor TFIIC (Slattery et al. 1983) , its activation and role in transcriptional regulation in the absence of DNA damage remained unclear (Tulin et al. 2002; Kraus and Lis 2003; Kim et al. 2004; Parvi et al. 2005 ). Here we report that progestin gene regulation and subsequent cell proliferation in breast cancer cells require a rapid and transient increase in PAR, mediated by activation of PARP-1. PARP-1 activation is the result of phosphorylation by the hormoneactivated cyclin-dependent kinase CDK2 at two consecutive serine residues, leading to enhanced PARylation capabilities. As PARP-1 is required for ligand-induced transcriptional activation following 17b estradiol and retinoic acid treatment (Parvi et al. 2005; ) and interacts with progesterone receptor (PR) (Sartorius et al. 2000) , we demonstrate the mechanism of PARP-1 activation in breast cancer cells. PARP-1 activation contributes to displacement of histone H1, an essential step for regulation of the majority of hormone-responsive genes and for the effect of progestins on cell cycle progression. Both global chromatin immunoprecipitation (ChIP) coupled with deep sequencing (ChIP-seq) and gene expression analysis show a strong overlap between PARP-1 and CDK2. Thus, progestin gene regulation involves a novel signaling pathway connecting CDK2-dependent activation of PARP-1 with histone H1 displacement, offering a potential target for endocrine control of breast cancer progression.
Results

PAR levels dramatically increase following hormone treatment
First, we estimated the levels of PAR and PARP-1 by immunofluorescence at different time points after hormone treatment of T47D-MTVL (T47D M ) breast cancer cells that carry a single integrated copy of a luciferase transgene driven by the mouse mammary tumor virus (MMTV) promoter (Truss et al. 1995) . Nuclear PAR levels increased dramatically after treatment with the synthetic progesterone analog R5020 for 15 min (Fig. 1A, left panel) . Levels of PAR markedly increased 5 min following hormone addition, remained high for 30 min, and returned to basal values after 60 min (Fig. 1B, top panel) . The increase in PAR and PARylated proteins following hormone treatment was blocked by the PARP inhibitor 3AB (Fig. 1B , top panel, dashed line; Supplemental Fig. S1A ). Concomitantly with the increase in PAR, the levels of PARP substrate NAD dropped after progestin treatment (Fig.  1B, bottom panel) . The decrease in NAD levels was due to PARP activity, as it was abrogated by 3AB. (Fig. 1B , bottom panel, dashed line). Thus, breast cancer cells respond to progestin treatment with a rapid and transient increase in PARylation of nuclear proteins catalyzed by the hormonal activation of members of the PARP family.
Activation of PARP plays a role in induction of the progesterone reporter gene in T47D M cells. The 14-fold increase in MMTV-luc transcription observed after 6 h of hormone treatment was significantly compromised following prior incubation with PARP inhibitor 3AB in a dose-dependent manner (Supplemental Fig. S1B ). Similar results were observed with the PARP inhibitors PJ34 and NAP (Supplemental Fig. S1C ). To date, 17 PARP family members have been identified, although PARP-1 is responsible for ;90% of PAR formed in cells (Ame et al. 2004) . To confirm that PARP-1 is indeed the PARP responsible for the increase in PAR levels observed following hormone treatment, we generated T47D M cells depleted of PARP-1 by stable expression of a specific shRNA (Fig. 1C) . We observed no phenotypic or growth abnormalities (Supplemental Fig. S2A ,B) in PARP-1 knockdown cell lines; however, we did observe that the hormonal activation of the MMTV transgene was reduced by >70% compared with control shRNA cell lines (Fig. 1D ). In addition, the induction of endogenous progesterone target genes c-Fos, DUSP1, and EGFR was also significantly reduced in the PARP-1 knockdown cell lines (Fig.  1E) . Treatment of T47D M cells with progestin induces a single round of proliferation, and this progestin-induced proliferation of T47D M cells was compromised in the absence of PARP-1 ( Fig. 1F ; Supplemental Fig. S2D) ; therefore, we conclude that gene induction and activation of cell proliferation by progestin depend on PARylation and an increase in PARP-1 activity.
CDK2 activates PARP-1 in response to hormone treatment
To test whether activation of PARP-1 is mediated by one of the hormone-activated kinases, we measured the effect of several kinase inhibitors on the formation of PAR after progestin treatment (Supplemental Table S1 ). Only Cdk2ii, an inhibitor of CDK2, significantly (P < 0.05) abrogated the levels of PAR following hormone treatment (Supplemental Fig. S3A) . Notably, inhibitors of the damage kinases ATM and ATR did not inhibit hormone-dependent PAR accumulation, suggesting a distinct signaling cascade from that activated during DNA damage. CDK2 is rapidly activated by progesterone in T47D M cells and plays an important role in hormone gene regulation (Lange 2008; Vicent et al. 2011) .
To confirm that CDK2 is involved in hormonal activation of PARP-1, CDK2 was knocked down in T47D M cells using specific siRNA. Depletion of CDK2 compromised the hormone-induced PAR accumulation, as determined by either Western blotting or ELISA ( Fig. 2A [cf. lanes 3 and 4], B, respectively). Thus, the increase in PAR levels observed as quickly as 5 min following hormone treatment is dependent on CDK2 activity. The observed decrease in cellular NAD levels following hormone treatment was also inhibited by the inhibition of CDK2 (Supplemental Fig. S3B ).
CDK2 in complex with Cyclin A and PR is required for the activation of some progesterone target genes (Narayanan et al. 2005; Vicent et al. 2011 ). Therefore, we tested whether genes dependent on PARP-1 activity are similarly affected by inhibition of CDK2. Hormonal induction of the MMTV-luc transgene-in addition to endogenous genes c-Fos, DUSP1, and EGFR-was markedly inhibited in the presence of the CDK2 inhibitor (Fig. 2C,D , respectively). Hormonal PARP-1 activation could be direct, since PARP-1 and CDK2 specifically interact following hormone treatment (Fig. 2E) , suggesting that PARP-1 is a direct target of hormone-activated CDK2. Interaction studies using HA-CDK2 truncations revealed a region of CDK2 between amino acids 150 and 200, comprising the second cyclin-binding domain (CBD), as responsible for the interaction with PARP-1 (Fig. 2F) . The use of GST-PARP-1 proteins revealed that the CDK2 interaction domain of PARP-1 resides within the automodification domain encompassing the BRCA1 C-terminal (BRCT) domain (amino acids 326-525), a known protein-protein interaction domain for other PARP-1-binding partners, including PARP2, DNA ligase III (Schreiber et al. 2002) , XRCC1 (Masson et al. 1998) , DNA Pol b (Dantzer et al. 2000) , histones, and transcription factors Oct1 and YY1 ( Fig. 2G ; Oei and Shi 2001) .
CDK2 phosphorylates PARP-1, resulting in a more catalytically active enzyme PARP-1 is phosphorylated by CDK2 in vitro (Fig. 3A) , and sequential in vitro phosphorylation and PARylation assays demonstrated that phosphorylated PARP-1 had a higher auto-PARylation activity as compared with unphosphorylated PARP-1 (Fig. 3B, cf. lanes 1 and 3) . The trans-PARylation of histone H1 was also enhanced by prior phosphorylation of PARP-1 by CDK2 (Fig. 3B , cf. lanes 2 and 4). This enhancement of PARylation is not merely stabilized by the CDK2-PARP-1 interaction. It needs enzymatic activity, demonstrated by a kinase-dead CDK2, which is unable to enhance PARylation (Supplemental M cells (Supplemental Fig. S5D ,E). The ability of CDK2 to enhance the PARylation activity of GST-PARP-1 phospho-null mutants (PARP-1 AAA/-AA; lanes 4-9) is significantly reduced compared with wild-type (wt) GST-PARP-1 (lanes 1-3), in contrast to the constitutively active PARylation capabilities observed using GST-PARP-1 phosphomimetic mutants (lanes 10-15), as determined by in vitro PARylation followed by immunoblot against PAR. (D, top panel) The protein levels of both endogenous PARP-1 and GST-PARP-1 (*) following cotransfection of siRNA (either control or PARP-1-specific) and plasmids encoding GST-PARP-1 si-resistant mutants in T47D M cell lines were determined by Western blotting using PARP-1 antibody. CDK2 levels are shown as a loading control. (Bottom panel) Phosphomimetic, but not phosphonull mutations of PARP-1 are able to rescue hormone-induced gene response following PARP-1 knockdown. Hormone induction of the MMTV-luc transgene, EGFR, and TiPARP 6 h following hormone treatment in T47D M cell lines cotransfected with control siRNA (black bars) or PARP-1 siRNA (white bars) and GST-PARP-1 si-resistant rescue plasmids as described above. Values are given as a fold change over T0 = 1. (E) The opening of the catalytic domain due to the conformational change predicted by phosphorylation is clearly visible comparing the predicted structure of the unphosphorylated (green) or phosphorylated (red) PARP-1 catalytic domains. The right panels highlight residues Gly988, Ser904, and Gly863, essential for NAD (ligand shown) binding, residing within the NAD-binding cleft (amino acids 859-908 surface representation), which are not adversely affected by the shift in the catalytic domain induced by PARP-1 phosphorylation. Fig. S4B ), although it interacts with PARP-1 (Supplemental Fig. S4C ). Thus, phosphorylation of PARP-1 by CDK2 and not solely the interaction between these two proteins is essential for PARP-1 activation.
To test whether hormone-dependent CDK2-mediated PARP-1 phosphorylation occurs in vivo, PARP-1 from control T47D M cells or from cells treated with R5020 with or without prior incubation with the inhibitor Cdk2ii (Supplemental Fig. S5A ) was analyzed by mass spectrometry. No significant phospho-peptides were found in the control sample, while three phospho sites were identified after hormone treatment, corresponding to Ser782, Ser785, and Ser786 of PARP-1. In cells treated with the CDK2 inhibitor, only the previously identified phospho site Ser782 (Mayya et al. 2009 ) was detected, suggesting that Ser785 and Ser786 are hormone-induced phospho sites dependent on CDK2 (Fig. 3C) . PARP-1 contains a potential RXL domain (Supplemental Fig S5B) commonly found in CDK substrates facilitating proper substrate orientation and recognition by binding to the cyclin partner of the CDK (Adams et al. 1996) . The phosphorylation of PARP-1 at Ser782, Ser785, and Ser786 by CDK2 is essential for the enhanced activity of PARP-1, as GST-PARP-1 Ser/Ala mutants greatly reduced the CDK2-enhanced activation of PARP-1 autoand trans-PARylation capabilities (Fig. 3C , cf. lanes 1-3 and 4-9). In contrast, phosphomimetic mutation of these sites (Ser/Asp) gave rise to a constitutively active PARP-1, the activity of which is not enhanced further by CDK2 phosphorylation (Fig. 3C , cf. lanes 1-3 and 13-15; Supplemental Fig. 5E ). The PARylation capabilities of PARP1 782 phospho-null (A-) and phosphomimetic (D-) mutants showed no significant changes (data not shown). As shown by PARP-1 being required for progesterone induction of target genes (Fig. 1E) , overexpression of phospho-null PARP-1 mutants acted as dominant-negative, inhibiting the progestin induction of target genes (Fig. 3D, black  bars) . Knockdown of PARP-1 resulted in impaired hormone induction (Fig. 3D, white bars) , rescued by the addition of the si-resistant phosphomimetic PARP-1 but not the phospho-null mutants (Fig. 3D) , confirming that the phosphorylation of PARP-1 is essential for the activation of downstream target genes.
We next asked whether this enhanced activity could be due to a structural change in the catalytic domain of PARP-1 induced by phosphorylation. The structure of the PARP-1 catalytic domain (Protein Data Bank [PDB] 3L3M) (Penning et al. 2005 ) was modeled mimicking phosphorylation at Ser782, Ser785, and Ser786 and revealed that the increase in negative charge results in the formation of a 3:10 helix (Lee et al. 2000) , giving rise to a more open catalytic domain (Fig. 3E) . This structural change significantly increases the exposition of the NAD acceptor site (Fig. 3E , surface representation) without affecting either the residues essential for NAD binding (Glu988, Ser904, or Gly863) (Fig. 3E, right panel) or the structural stability of the catalytic domain as a whole (Supplemental Fig. S6 ), thus supporting the hypothesis that phosphorylated PARP-1 is more catalytically active.
Hormone-induced gene regulation depends on both CDK2 and PARP-1 on a global scale To obtain a global view of PARP-1 and CDK2 dependence in progesterone gene regulation, we performed gene expression microarrays with T47D
M cells untreated and treated with the progestin R5020 in the presence or absence of the PARP inhibitor 3AB or the CDK2 inhibitor Cdk2ii. We focused on the combined data set, which represents the genes that are significantly up-regulated or down-regulated in both arrays (Fig. 4A,B, Venn diagram) . Eighteen percent of the genes in the combined list are dependent on CDK2 alone, and 12% depend on PARP exclusively. Only 15% of progestin-regulated genes in the combined list were independent of these two enzymes, while 85% (3219 genes in the combined data set) depended on either PARP-1 or CDK2 activity, with the majority (55%) depending on both. A heat map representation ( Fig. 4A ) and correlation analysis (Supplemental Fig. S7C ) clearly show that induced or repressed genes are also affected in a similar manner and to a similar extent by both inhibitors (R = 0.69). A similar pattern of PARP-1 and CDK2 dependence is found comparing up-regulated genes or down-regulated genes (Fig. 4C) . Gene-specific mRNA determinations by RT-PCR were used to validate this dependence on the enzymatic activities of both CDK2 and PARP-1 and confirmed the array results (Fig. 4D) . Consistent with progesterone-induced cellular proliferation, pathway analysis of PARP-and CDK2-dependent gene lists showed an enrichment of MAPK signaling and cancer pathways (Supplemental Table S3 ). Gene ontology (GO) term biological functional analysis was consistent with previous reports showing an enrichment of stress, transcription, cell signaling (intracellular signaling cascades, kinase cascades, and enzyme-linked receptor signaling), cell proliferation, and metabolic functions (Supplemental Tables S4-S7) .
As previously published (Vicent et al. 2011) , we detected recruitment of PR and CDK2 to the MMTV nucleosome B as early as 1 min after hormone induction (Fig. 5A ). Since histone H1 is one of the main targets of PARP-1 and displacement of histone H1 is one of the initial steps in hormone-responsive promoters (Vicent et al. 2011 ), we measured H1 loading by ChIP. We confirmed that histone H1 is displaced from the MMTV promoter already 1 min after hormone treatment (Fig. 5A ) and remains low until 30 min (Supplemental Fig. S8A ). The concomitant recruitment of PARP-1 and CDK2 and H1 displacement were confirmed at other progesterone-binding sites (PRBs) (Fig. 5B, right panel) . As it has been reported that PARP-1 and histone H1 are mutually exclusive at gene promoters (Krishnakumar et al. 2008 ), we performed a ChIP assay in PARP-1 knockdown cell lines. PARP-1 enzymatic activity is not essential for the initial recruitment of PARP1 or PR to target promoters, as depletion of PARP-1 protein (shRNA) or enzymatic activity (3AB) did not abrogate recruitment of PR to the MMTV promoter ( Fig. 5C ; Supplemental Fig. 8A, respectively) . In marked contrast, the displacement of histone H1 is dependent on PARP-1 activity and hence PARylation, as hormone-induced H1 removal is blocked in PARP-1-depleted cell lines (Fig. 5C , cf. lanes 1-4 and 5-8) and in cells treated with 3AB (Supplemental Fig. S8A) . We confirmed by re-ChIP experiments that following hormone treatment, binding of PARP-1 and CDK2 takes place on the same promoter (Fig. 5D) . Moreover, hormone-dependent recruitment of PARP-1 and CDK2 as well as H1 displacement were dependent on the catalytic activities of both enzymes, as they were blocked by prior treatment of T47D M cells with either 3AB or Cdk2ii (Supplemental Fig. 8B ). ChIPseq analysis with antibodies to PARP-1 and CDK2 was performed at 0, 5, and 30 min following R5020, and a few thousand new peaks were found after hormone treatment (Fig. 5E, table) , showing a significant corecruitment of Fig. S7A,B) . (B) Venn diagram of progestin-regulated genes (bold; percentage of genes), indicating the dependence on CDK2 (18%), PARP-1 (12%), or both CDK2 and PARP-1 (intersection 55%), or independent of the two enzymes (15%). (C) Up-regulated and down-regulated progestin-dependent genes are similarly affected by the inhibition of PARP-1 and CDK2. (D, panel i) mRNA expression levels of CDK2-and PARP-1-dependent genes TiPARP and IGFBP5 was determined by quantitative RT-PCR (qRT-PCR) in cells treated with R5020 for 6 h in the presence or absence of 3AB or CDK2ii. (Panel ii) mRNA expression levels of CDK2-and PARP-1-independent genes STAT1 and ESR1 was determined by qRT-PCR in cells treated with R5020 for 6 h in the presence or absence of 3AB or CDK2ii. (Panel iii) mRNA expression levels of CDK2-dependent genes CASP7 and AFTPH were determined by qRT-PCR in cells treated with R5020 for 6 h in the presence or absence of 3AB or CDK2ii. (Panel iv) mRNA expression levels of PARP-1-dependent genes SNIP and FZD4 were determined by qRT-PCR in cells treated with R5020 for 6 h in the presence or absence of 3AB or CDK2ii (mean fold induction over T0 6 SEM).
both proteins (Fig. 5E, Venn diagram) . Globally, for both PARP-1 and CDK2, we observed peaks recruited and maintained at 5 and 30 min following hormone treatment (Supplemental Fig. 9 ). Visualization of PARP-1 occupancy on chromatin specifically on a 2-kb region surrounding the CDK2 hormone-dependent peaks showed that PARP-1 CDK2 enhances PARP1 enzyme activity is enriched within these regions (Fig. 5F, left panel) . Further supporting the cooperation of these two enzymes, CDK2 occupancy is also enriched on chromatin in regions surrounding PARP-1 hormone-dependent peaks (Fig. 5F , right panel). Both CDK2 and PARP1 were enriched around PRbinding sites, supporting a role of PR in recruiting these proteins to progestin-regulated regions (Fig. 5G) .
Discussion
In recent years, a DNA damage-independent role for PARP-1 in both the activation and repression of transcription has emerged (Kraus and Lis 2003; Luo and Kraus 2012) , which can or cannot require PARP-1 enzymatic activity (Hassa et al. 2003; Ju et al. 2004; Cohen-Armon et al. 2007 ). Several lines of evidence link PARP-1 with nuclear receptor (NR)-mediated transcription. PARP-1 inhibition has been shown to block estrogen receptor a (ERa)-, androgen receptor (AR)-, retinoic acid receptor (RAR)-, and thyroid hormone receptor (T 3 R)-dependent gene activation , but the role of PARP-1 in progesterone gene regulation has not been reported. Here we show that PARP-1 enzymatic activity is rapidly enhanced after progestin treatment of breast cancer cells and provide a molecular mechanism for this effect; namely, phosphorylation by hormone-activated CDK2. PARP-1 activation leads to a global increase in PAR levels that is essential for the induction or repression of the majority of progesterone-regulated genes. These findings differ from previous results by Parvi et al. (2005) showing that RAR-mediated transcription requires PARP-1, which, independent of its catalytic activity, converts Mediator from the inactive to the active state. Although Mediator and CDK2 both bind the BRCT domain of PARP-1, in progestin-treated breast cancer cells, the outcome is PARP-1 phosphorylation and enhancement of its enzymatic activity, likely by opening the NAD-binding cleft of its catalytic domain. Additional experiments will be needed to explore whether activated PARP1 also has an effect on the Mediator state in progestin-treated breast cancer cells.
Kinase-induced activation of PARP-1 in the absence of DNA damage was demonstrated previously to be essential for expression of Elk1 target genes and for promoting cell proliferation (Cohen-Armon et al. 2007 ). In contrast with a previous study (Inbar-Rozensal et al. 2009 ), we observed that although PARP-1 is not essential for breast cancer cell growth in response to serum factors, it is indispensable for progesterone-induced cell proliferation after serum starvation. This effect of PARP-1 on hormonal response seems to be specific for PR, since ERa and PARP1 do not interact, and PR and PARP-1 expression levels positively correlate in proliferative lesions, whereas the levels of ER and PARP-1 do not (Ghabreau et al. 2004) .
Although both PARP-1 and CDK2 have been previously implicated in the transcription of hormone-regulated genes (Parvi et al. 2005; Moore and Weigel 2011; Vicent et al. 2011) , the molecular mechanism of PARP-1 activation and the pathway connecting these two enzymes had not been established. Our results identify a new signaling pathway going from activated PR to activated CDK2 and PARP-1. Recently, the possibility of post-translational modification of PARP-1 mediating its activation has received considerable attention. Gagné et al. (2009) used a broad proteomic screen to identify several potential PARP-1 phosphorylation sites, including Ser372 and the residues Ser782/ Ser785 and Ser786 identified here. Subsequent biochemical studies have confirmed that phosphorylation of S372 and Thr373 by ERK1/2 enhances PARP-1 activation following DNA damage (Kauppinen et al. 2006) . We provide evidence showing that in the absence of DNA damage, phosphorylation at Ser785 and Ser786 by CDK2 enhances PARP-1 activation in response to progesterone. The role of phosphatases in PARP-1 control is of potential interest, as the increase in PAR levels induced by progesterone is a transient event.
In addition to elucidating the molecular basis of hormonal PARP1 activation, we also provide a possible mechanism for the role of PARP1 in gene regulation. Both PARP-1 and CDK2 are recruited to the large majority of progestin target genes, where they cooperate in displacement of the linker histone H1. We showed previously that H1 displacement is the first step in progestinmediated gene regulation and that NURF and CDK2/ Cyclin E participate in this process, which takes place within 1 min after hormone addition (Vicent et al. 2011) . We now show that the PARylation activity of PARP-1 is also required for the displacement of histone H1. Highly negatively charged PAR covalently attached to target proteins has the potential to alter protein-protein interactions and biochemical activities as well as the retention of proteins in the chromatin environment (Luo and Kraus 2012) . As we observed a transient increase in PAR, the precise role of PAR hydrolysis by PAR glycohydrolase (PARG) to free either PAR or mono(ADP-ribose) will be of particular interest in the future.
We propose the following model ( This study provides further insight into previous findings proposing a role for PARP-1 activation in signaling pathways required for downstream chromatin modification and gene regulation in the absence of DNA damage. Given the multiplicity of known PARP interactors in conjunction with the wide array of potential PARylation targets, it remains to be explored whether PARP-1 fulfils other functions in gene regulation and whether knowledge of this new pathway can be used for the pharmacological management of breast cancer (InbarRozensal et al.2009 ).
Materials and methods
Cell culture
T47D
M cells were used for all experiments unless otherwise stated. For hormone induction experiments, cells were grown in RPMI medium without Phenol Red, supplemented with 10% dextran-coated charcoal-treated FBS (DCC/FBS) after 24 h in serum-free conditions; cells were incubated with R5020 (10 nM) or vehicle (ethanol) as described (Vicent et al. 2011) . Inhibitor concentration and duration are given in Supplemental Table S1 .
PAR purification
PAR was purified essentially as described (Aboul-Ela et al. 1988) . Briefly, 5 3 10 6 human embryonic kidney (HEK) 293T cells were grown to confluency in 150-mm plates. The growth medium was removed, and the cells were exposed to 200 J/m 2 UVB irradiation. The medium was replaced, and 30 min later, the cells were harvested with trypsin. The resultant cell pellet was washed twice with PBS and precipitated with 20% final volume TCA. Following centrifugation at 1800g for 10 min at 4°C, pellets were washed with 20% TCA and twice with 100% ethanol and airdried. The pellets were resuspended in 1 M KOH and 50 mM EDTA and vortexed to mix. Extracts were then incubated for 2 h at 60°C with gentle agitation. A DHBB column was equilibrated with AAGE9 buffer (250 mM ammonium acetate at pH 9.0, 6 M guanine HCl). Samples were passed through the column twice, and the column was then washed with AAGE9 buffer before a final wash of 1 M ammonium acetate (pH 9.0). PAR was eluted from the resin with water, lyophilized overnight, and stored at À80°C until required.
In vitro PARylation assay
Unless otherwise indicated, the standard reaction contained 500 mg of wild-type PARP-1 (Trevigen) or 1 mg of GST-PARP-1 phosphomutants purified from mammalian cells previously phosphorylated in vitro by CDK2 as described (Supplemental Material). One-hundred micrograms of histone H1 (Millipore) and 200 ng of activated DNA were incubated in PARP-1 reaction buffer (400 mM NAD, 50 mM Tris-HEPES at pH 8.0, 0.15 mM KCl, 10 mM MgCl 2 ) for 30 min at 25°C. The reactions were stopped by the addition of 43 SDS loading buffer and analyzed on SDS-PAGE and Western blot probing for the presence of PAR using PAR-specific antibodies.
PAR-capture ELISA
Hormone and inhibitor treatments (Supplemental Table S1 ) were carried out as described, and sample preparation was carried out as follows: At the required time point, cells were washed twice with ice-cold PBS and scraped in lysis buffer (0.4 M NaCl, 1% Triton X-100) plus protease inhibitors. Cell suspensions were then incubated for 30 min on ice with periodic vortexing. The disrupted cell suspension was centrifuged at 10,000g for 10 min at 4°C, and the supernatant was recovered, snap-frozen, and stored at À80°C until required. Ninety-six-well black-walled plates were incubated with 2 ng/mL anti-PAR monoclonal antibody (Trevigen) in 50 mM sodium carbonate (pH 7.6) overnight at 4°C. The plates were washed once with PBS and blocked with blocking solution (5% semiskimmed milk powder, 0.1% Tween 20, 25 mM Tris at pH 7.4, 150 mM NaCl) for 1 h at room temperature. The plate was then washed four times in PBS and 0.1% Tween 20. One-hundred microliters of each sample (20 mg of total protein) or a PAR standard was applied and incubated for 1.5 h at room temperature. The plate was washed four times with PBS and 0.1% Tween 20 and incubated with anti-PAR rabbit polyclonal antibody (Trevigen) for 1.5 h at room temperature. The plate was washed four times with PBS and 0.1% Tween 20 and incubated with anti-rabbit HRP conjugate secondary antibody (5% semiskimmed dried milk) for 1.5 h at room temperature. The plate was washed six times with PBS and 0.1% Tween 20, and PAR was identified via incubation with TACs Sapphire (Trevigen) for 10 min in the dark. The reaction was terminated with 5% phosphoric acid, and the absorbance at 450 nm and 520 nm was recorded.
NAD depletion assay
T47D
M cells were either left untreated or treated with the inhibitor indicated (Supplemental Table S1 ) prior to R5020 addition as described. NAD concentration was determined as described (Jacobson and Jacobson 1976) . At T = t, cells were washed with ice-cold PBS and incubated in 0.5 M PCA for 20 min on ice. An equal volume of KOH (1 M)/K 2 HPO 4 (0.33 M) (pH 7.0) was added, and the samples were vortexed and incubated for 20 min on ice. Samples were spun at 10,000 rpm for 2 min at 4°C, and the supernatant was stored at À20°C. The quantification of NAD was carried out as follows: Samples were added to an equal volume of reaction buffer (200 mM Bicine at pH 7.8, 1 mg/mL BSA, 1 M EtOH, 10 mM EDTA at pH 8.0, 4 mM phenazine). Onetenth of the reaction volume of alcohol dehydrogenase was added and incubated for 30 min at 30°C. The reaction was terminated with a 0.33 sample volume of 12 mM iodoacetate, and the absorbance at 570 mM was measured.
Purification of HA-CDK2 proteins for in vitro PARylation assays HEK 293T cells were transfected with pCMV-neo-CDK2 HAwt (Addgene plasmid depository 1884) or pCMV-neo-CDK2HAdn (Addgene plasmid depository 1885). Cells were serially diluted, and positive clones were selected with G418 (1 mg/mL). Expression of CDK2-HAwt or CDK2-HAdn was confirmed by Western blot as described using HA-specific antibody (Abcam). Purification of CDK2-HA proteins was carried out under nondenaturing conditions as follows: Cell lysates from 6 3 10 6 cells were prepared and incubated with 100 mL of prewashed anti-HA agarose slurry (Pierce, Thermo Scientific). Samples were incubated overnight at 4°C with gentle end-over-end mixing on a rocking platform. Agarose beads were washed three times with TBS-Tween 20 (0.05%) prior to HA-protein elution using 1 mg/mL HA-peptide (Pierce, Thermo Scientific) for 15 min at 30°C.
Generation of HA-CDK2 truncations for PARP-1 interaction studies CDK2 truncations, including the HA tag (Fig. 2F ) PCR-amplified from pCMV-neo-CDK2-HA (Addgene plasmid depository 1884), were subcloned using BamHI into empty pCMV-neo. PCR primers are available on request. The correct orientation was confirmed by sequencing using the Bglob-intron-F sequencing primer (CTGGTCATCATCCTGCCTTT). T47D M cells were transfected as described with CDK2-HA-encoding plasmids; 48 h later, cell lysates were prepared and immunoprecipitated using anti-HA-specific antibody overnight at 4°C end over end. The interaction of the CDK2-HA truncated proteins with PARP-1 was detected by Western blot using PARP-1-specific antibody.
Additional methods are provided in the Supplemental Material.
